QuidelOrtho Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Brian J. Blaser
- Full Time Employees
- 6,500
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 9975 Summers Ridge Road San Diego CA United States of America 92121
- IPO Date
- Feb 1, 1991
- CIK
- 0001906324
- Website
- quidelortho.com
- Similar Companies
- Business
- QuidelOrtho Corporation (Nasdaq: QDEL), founded in 1979 and headquartered in San Diego, California, develops, manufactures and markets in vitro diagnostic technologies for point-of-care settings, clinical laboratories and transfusion medicine worldwide, serving customers in over 140 countries across North America, Europe, the Middle East, Africa, China and other regions. The company offers a comprehensive portfolio of products and services including visually-read lateral flow assays such as QuickVue for infectious diseases, reproductive health and cardiac markers; Sofia fluorescent immunoassay analyzers and tests; direct fluorescent antibody tests; molecular diagnostics via LYRA real-time PCR assays and the forthcoming LEX Diagnostics platform; clinical chemistry and immunodiagnostic systems like VITROS; donor screening with Ortho Summit, VERSEIA and VITROS systems; pre-transfusion testing through ORTHO VISION analyzers and ORTHO CONNECT software; semi-automated immunohematology solutions including ORTHO Workstation and ORTHO OPTIX Reader; and Ortho Care services and informatics for lab efficiency. In recent developments, QuidelOrtho announced in June 2025 a strategy to accelerate growth in point-of-care molecular diagnostics by intending to acquire full ownership of LEX Diagnostics for approximately $100 million upon U.S. FDA clearance expected in late 2025 or early 2026, while discontinuing development of its Savanna platform; the company also completed a major debt refinancing in August 2025, issuing $1.15 billion in 5-year Term Loan A, $1.45 billion in 7-year Term Loan B, a $100 million delayed draw facility and a $700 million revolving credit facility to extend maturities, reduce amortization and enhance financial flexibility.
QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
QuidelOrtho: Too Much Uncertainty Around Earnings Keeping Short-Interest Elevated
QuidelOrtho (QDEL) Moves 32.2% Higher: Will This Strength Last?
QuidelOrtho Appoints Micah Young as Chief Financial Officer
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
Is QuidelOrtho Corp (QDEL) a Bargain After 3.3% Drop? GF Value Says Undervalued
Is the Options Market Predicting a Spike in QuidelOrtho Stock?
QuidelOrtho (QDEL) Up 24.1% Since Last Earnings Report: Can It Continue?
QuidelOrtho's Respiratory Exposure Remains a Key Near-Term Risk
QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies
A Look at QuidelOrtho Corp (QDEL) After 6.0% Gain -- GF Value $37.21 vs Price $13.06
When Blood Compatibility Becomes a Pregnancy Risk
QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences
Hantavirus outbreak: these 3 stocks are poised to rip higher
QDEL Stock Down as Q1 Earnings Miss Estimates, Revenues Down Y/Y
QuidelOrtho Corporation (QDEL) Q1 2026 Earnings Call Transcript
QuidelOrtho (QDEL) Reports Q1 Loss, Tops Revenue Estimates
QuidelOrtho Reports First Quarter 2026 Financial Results
Earnings Preview: QuidelOrtho (QDEL) Q1 Earnings Expected to Decline
QuidelOrtho Corp (QDEL) Shares Surge 6.1% -- What GF Score of 60 Tells Investors